Clinical-stage biopharmaceutical Company
Maximizing health span via increasing restorative sleep
In the lab
US, Canada, UK · Discovery
Translational research
LABORATORIES
Carnyx is developing first-in-class molecular assets to extend restorative non-REM sleep and unlock regenerative biology for improved health.
Endorsed by
The Carnyx Technology
A team of expert scientists, drug developers and commercial strategists with a proven record of taking new therapies to patients. Our goal is to understand, validate, and obtain fast-track regulatory approval for game-changing novel therapeutics in human diseases.
Peptidic Therapies to improve, delay, and reverse disease.
We are developing peptide-based therapies that selectively induce restorative NREM sleep without the unfavourable side effects of traditional sleep medications.
2
First-in-class assets
3x
Drugs in advanced clinic development
+50 yr
Combined R&D leadership
$12m
raised Capital to date
Clinincal candidate · CNYX-005
Target
Improved NREM restorative Sleep
Modality
Orally administered, small molecule
Programs in Active Development
Two therapeutic areas where current options are insufficient and our molecular approach offers a clear, mechanistic advantage. From an oral sleep drug, with no drowsiness, to an eye drop, retinitis pigmentosa drug, every asset is designed for fit-for-purpose delivery.
CNYX-005
Sleep is the Foundation of healthspan
Sleep deficiency increases the risk of type 2 diabetes, obesity, heart disease and high blood pressure. Improved sleep duration and regularity are essential for longevity — and poor sleep is independently associated with mortality.
CNYX-001
Retinitis pigmentosa, treated independent of genetic cause
RP affects ~1.5 million people worldwide and is a leading cause of inherited blindness. With 1 in 3,000 children now diagnosed and limited effective treatments available, our localized therapy — administered by eye-drop — has shown impressive biological effects across multiple genetic causes.
Platform thesis
Longevity is quantity×quality
True longevity integrates both the years lived and the vitality, independence and joy within them. Carnyx technologies, via extended restorative sleep, are designed to reduce inflammation, protect against DNA damage, and facilitating cellular waste clearance.
01
Inflammation
Chronic-state reduction
02
DNA damage
Genomic stability
03
Autophagy
Waste clearance
Development Pipeline
Two clinical-stage assets advancing through IND-enabling studies, with additional discovery programs in our longevity platform. All compounds are wholly-owned by Carnyx with strong composition-of-matter and use patents.
The experts behind the science
A small team of senior drug developers, translational scientists and commercial operators with prior exits, clinical candidate nominations, and deep domain expertise across sleep medicine, oncology and cellular ageing.
-
Dr. Patrick Gunning
Chief Executive Officer
Patrick T. Gunning is a Professor of Molecular Therapeutics at the University of Glasgow, Professor of Chemistry at the University of Toronto and previously a Canada Research Chair in Medicinal Chemistry, founder and inaugural Director of Centre for Medicinal Chemistry.
Dr. Gunning earned his Ph.D. from the University of Glasgow and completed postdoctoral studies at Yale University. He has authored over 140 research publications and received numerous accolades, including the Boehringer Ingelheim Young Investigator Award, the RSC MedChemComm Emerging Investigator Lectureship, and recognition as one of Canada's Top 40 Under 40. Patrick is a Fellow of the Royal Society for Chemistry.
Beyond academia, he has co-founded multiple biotech companies, including Janpix Inc., publicly tradedCentessa Pharmaceuticals (CNTA) which was recently bought by Eli Lilly in H1 2026 for $7.8 Billion USD., Dunad Therapeutics, Dalriada Drug Discovery, HDAX Therapeutics, and Carnyx Therapeutics, collectively securing over $100 million in funding. In 2021, Dunad Therapeutics entered a strategic collaboration with Novartis, potentially worth up to $1.3 billion, to develop next-generation oral targeted protein degrader therapies.
-
Dr. Mark Lindsay
Chief Medical Officer
Dr. Mark Lindsay is a Doctor of Chiropractic and graduate of Palmer Chiropractic College, renowned for his work with Super Bowl Champions, Stanley Cup Champions, Major League Baseball Championship teams and elite athletes including multiple World and Olympic Champions.
Dr. Lindsay has worked extensively with elite athletes and teams over the past 35 years to enhance performance and reduce injury risk. Dr. Lindsay is a member of the College of Chiropractors of Ontario; a Diplomate with the American Chiropractic Neurology Board, a member of the Ontario Chiropractic Association, a member of the Colorado Chiropractic Association and a 2025 PhD Candidate in the Neuroscience Program at Queens University in Kingston, Ontario.
Dr. Lindsay has completed over 2500 hours of course work through the Carrick Institute for Graduate Studies and has spent the past two decades studying under the late French osteopath, Dr. Guy Voyer in the Fascia Fellowship Program. Mark is the author of the book “Fascia: Clinical Applications for Health and Human Performance” along with 10 research publications.
Mark is founder of Dr. Mark Lindsay Chiropractic Professional Corp, Lindsay Sports Therapy and co-founder of multiple biotech companies including: Carnyx Therapeutics, Kelvin Therapeutics and Entourage Diagnostics. Mark is also a Research Fellow with the Steadman Philippon Research Institute in Vail, Colorado. Dr. Lindsay was named the “Outstanding Field Doctor” by Canadian Chiropractic Sports Fellowship in 1996, following his work with double Olympic Champion and World Record Holder, Donovan Bailey.
-
Terry Butler
Chief Financial Officer
Terry Butler is a seasoned financial strategist with over 30 years of leadership experience driving growth, capital formation, and operational excellence across multiple sectors. As Chief Financial Officer of Carnyx Technology, he leverages deep expertise in investment analysis, fundraising strategy, and risk management to position the company for sustainable expansion.
His track record includes leading Etapestry.com as its founding CFO and board member through its first round of institutional funding from HarbourVest. Terry played a key role in scaling one of the first cloud‑based fundraising platform companies, culminating in a successful acquisition by Blackbaud (BLKB).
Previously, as founder and CFO of StemSource, Terry played a key role in establishing one of the first stem cell companies in the world. Within 12 months of closing the first institutional round of funding, he successfully sold the business to Macropore, Inc. (XMP) at a 10x multiple of the previous round.
Terry’s career reflects a consistent ability to attract investment, optimize capital structures, and deliver shareholder value—making him a trusted partner for investors seeking disciplined growth and long‑term returns.
-
Dr. Mark Bell
Chief Technology Officer
Mark Bell is a seasoned medicinal chemist with over two decades of experience spanning the biotech industry, contract research organizations (CROs), and academic drug discovery. He is the co-founder and Chief Technology Officer of Tay Therapeutics, where he has led the discovery and development of several innovative therapeutic candidates.
Mark spearheaded the discovery of Repibresib, a topical soft-drug pan-BET inhibitor currently in Phase 2a clinical trials for vitiligo, and VYN202, a BD2-selective oral BET inhibitor in Phase 1b trials for psoriasis. He also led the development of TAY-R1, an oral small molecule gene therapy targeting rare genetic diseases such as recessive dystrophic epidermolysis bullosa and Duchenne muscular dystrophy.
Mark is a co-founder of Hawkhill Therapeutics, focused on obesity and sarcopenia, and Entourage Diagnostics focused on proteomic biomarker analysis. During his time at the integrated drug discovery CRO Dalriada, he led the delivery of a preclinical candidate for postoperative pain for Antibe Therapeutics. While working with the Drug Discovery Unit at the University of Dundee he led on the discovery of a topical soft-drug SMO inhibitor preclinical candidate for Gorlin syndrome. At Almac Discovery, he contributed to the development of Phase 1b oncology candidates targeting Wee1 and Akt. He has provided strategic consulting for KelticPharma Therapeutics on their PfCLK3 malaria program enabling successful proof-of-concept in the SCID mouse model and transition to LO.
Mark is an inventor on 16 published patents across inflammation, rare diseases, and oncology therapeutic areas, reflecting his deep commitment to advancing translational science and improving patient outcomes.
Partner with us to extend health span
We are actively engaging with investors, strategic pharma partners, and clinicians interested in our retinitis pigmentosa and sleep programs. Reach out to schedule a confidential overview.